Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds

Gastrointestinal Endoscopy

Volumn 57, Issue 1, 2003, Pages 23-29

  Rulyak, Stephen J ^a   Kimmey, Michael B ^a   Veenstra, David L ^a   Brentnall, Teresa A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SCREENING; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DYSPLASIA; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FAMILIAL CANCER; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; MEDICAL CARE; MEDICAL DECISION MAKING; PANCREAS CANCER; PANCREAS RESECTION; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL;

EID: 0037283297     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1067/mge.2003.28     Document Type: Article

References (33)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Lynch HT, Smyrk T, Kern SE, Hruban RH, Lightdale CJ, Lemon SJ, et al. Familial pancreatic cancer: a review. Semin Oncol 1996;23:251-5.
3. Brentnall TA. Cancer surveillance of patients from familial pancreatic cancer kindreds. Med Clin North Am 2000;83:707-18.
4. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999;131:247-55.
5. Cubilla AL, Fitzgerald PH. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 1976;36:2690-8.
6. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998;22:163-9.
7. DiGiuseppe JA, Hruban RH, Offerhaus GJ, Clement MJ, van den Berg FM, Cameron JL, et al. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 1994;144:889-95.
8. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997;21:205-17.
9. DiGiuseppe JA, Hruban RH, Goodman SN, Polak M, van den Berg FM, Allison DC, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994;101:684-8.
10. Kloppel G, Bommer G, Ruckert K, Seifert G. Intraductal proliferation in the pancreas and its relationship to human and experimental carcinogenesis. Virchows Arch 1980;387:221-33.
11. Klimstra DS, Hameed MR, Marrero AM. Ductal proliferative lesions associated with infiltrating ductal adenocarcinoma of the pancreas. Int J Pancreatol 1994;16:224-5.
12. Hruban RH, Wilentz RE, Goggins M, Offerhaus GJ, Yeo CJ, Kern SE. Pathology of incipient pancreatic cancer. Ann Oncol 1999;10(suppl 4):S9-11.
13. Rulyak SJ, Brentnall TA. Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology 2001;1:477-85.
14. Martin SP, Ulrich CD. Pancreatic cancer surveillance in a high-risk cohort. Is it worth the cost? Med Clin North Am 2000;84:739-47.
15. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001;54:425-34.
16. Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001;96:417-23.
17. Sakorafas GH, Farnell MB, Farley DR, Rowland CM, Sarr MG. Long-term results after surgery for chronic pancreatitis. Int J Pancreatol 2000;27:131-42.
18. Lynch HT, Brand RE, Lynch JF, Fusaro RM, Smyrk TC, Goggins M, et al. Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families. Gastroenterology 2000;119:1756-60.
19. Davis B, Lowy AM. Surgical management of hereditary pancreatic cancer. Med Clin North Am 2000;84:749-59.
20. Pfau PR, Chak A. Endoscopic ultrasonography. Endsocopy 2002;34:21-8.
21. Bureau of Labor Statistics, United States Department of Labor. Available at: http://www.bls.gov/cpi/home.htm.
22. Sahai AV, Mauldin PD, Marsi V, Hawes RH, Hoffman BJ. Bile duct stones and laparoscopic cholecystectomy: a decision analysis to assess the roles of intraoperative cholangiography, EUS, and ERCP. Gastrointest Endosc 1999;49:334-43.
23. Ray NF, Thames M, Gardner E, Chan JK. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998;21:296-309.
24. Wilson LS, Lightwood JM. Pancreatic cancer: total costs and utilization of health services. J Surg Oncol 1999;71:171-81.
25. Porter GA, Pisters PW, Mansyur C, Bisanz A, Reyna K, Stanford P, et al. Cost and utilization impact of a clinical pathway for patients undergoing pancreaticoduodenectomy. Ann Surg Oncol 2000;7:484-9.
26. National Center for Health Statistics. Life table for the total population: United States 1997. National Vital Statistics Report. Volume 27(Number 28);1999.
27. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
28. Stevens R, Adler A, Gray A, Briggs A, Holman R. Life-expectancy projection by modelling and computer simulation (UKPDS 46). Diabetes Res Clin Pract 2000;50(Suppl 3):S5-13.
29. Eddy DM. Screening for cervical cancer. Ann Intern Med 1990;113:214-26.
30. van der Maas PJ, de Koning HJ, van Ineveld BM, van Oortmarssen GJ, Habbema JD, Lubbe KT, et al. The cost-effectiveness of breast cancer screening. Intl Cancer 1989;43:1055-60.
31. Provenzale D. Cost-effectiveness of screening the average-risk population for colorectal cancer. Gastrointest Endosc Clin N Am 2002;12:93-109.
32. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med 1998;339:380-6.
33. Eberle MA, Pfutzer R, Pogue-Geile KL, Bronner MP, Crispin D, Kimmey MB, et al. A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. Am J Hum Genet 2002;70:1044-8.